Valuation : Forte Biosciences

Market Cap 1.94B 1.67B 1.57B 1.43B 2.69B 185B 2.7B 18.59B 7.25B 93.55B 7.28B 7.12B 310B P/E 2026 *
-17.2x
P/E 2027 * -18.9x
Enterprise Value 1.94B 1.67B 1.57B 1.43B 2.69B 185B 2.7B 18.59B 7.25B 93.55B 7.28B 7.12B 310B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+0.03%
1 week+0.09%
Current month+0.51%
1 month+0.60%
3 months+303.72%
6 months+154.77%
Current year+182.32%
1 week 76.92
Extreme 76.92
77
1 month 76.51
Extreme 76.51
77
Current year 15.51
Extreme 15.51
77.2
1 year 10.11
Extreme 10.11
77.2
3 years 4.11
Extreme 4.11
77.2
5 years 4.11
Extreme 4.11
786.75
10 years 4.11
Extreme 4.11
1,349.75
Manager TitleAgeSince
Chief Executive Officer 55 2017-12-31
Director of Finance/CFO 59 2020-02-29
Chief Operating Officer - 2020-09-30
Director TitleAgeSince
Chairman 55 -
Director/Board Member 58 2020-05-31
Director/Board Member 79 2022-03-15
Date Insider Type Main position Quantity % Market Cap.
8/27/26 Issuer sale

Director

-51,353 0.2508%
8/27/26 Issuer sale

Director

-54,353 0.2654%
8/27/26 Issuer sale

Director

-55,353 0.2703%

Financials

2026 *2027 *
Net sales - -
Net income -91.11M -78.51M -73.61M -67.2M -127M -8.71B -127M -873M -341M -4.4B -342M -335M -14.58B -107M -92.55M -86.77M -79.21M -149M -10.26B -150M -1.03B -402M -5.18B -403M -394M -17.18B
Net Debt - -
Logo Forte Biosciences
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Employees
23
Sector
-
Date Price Change Volume
26-08-26 US$76.99 +0.03% 1,400,110
26-08-25 US$76.97 +0.03% 1,235,752
26-08-24 US$76.95 +0.04% 1,255,679
26-08-21 US$76.92 +0.04% 2,012,128
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
76.99USD
Average target price
73.00USD
Spread / Average Target
-5.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBRX Stock